Johns Hopkins Bloomberg School of Public Health

Drop in Convalescent Plasma Use at U.S. Hospitals Linked to Higher COVID-19 Mortality Rate

Analysis suggests decline in convalescent plasma use in U.S. hospitals from November 2020 to February 2021 may have led to as many as 29,000 excess COVID-19 deaths

Newswise — A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter’s surge.

U.S. hospitals began treating COVID-19 patients with convalescent plasma therapy—which uses antibody-rich blood from recovered COVID-19 patients—in the summer of 2020 when doctors were looking to identify treatments for the emerging disease. By the spring of 2021, doctors in the United States had treated over 500,000 COVID-19 patients with convalescent plasma. The use of convalescent plasma started declining late in 2020 after several large clinical trials showed no apparent benefit.

The researchers’ analysis suggests that the decline in convalescent plasma use might have led to more than 29,000 excess COVID-19 deaths from November 2020 to February 2021.

The study was published online June 4 in the journal eLife.

“Clinical trials of convalescent plasma use in COVID-19 have had mixed results, but other studies, including this one, have been consistent with the idea that it does reduce mortality,” says study senior author Arturo Casadevall, MD, PhD, Alfred and Jill Sommer Professor and Chair of the Department of the Molecular Microbiology and Immunology at the Bloomberg School.

The study was done in collaboration with researchers at Michigan State University and the Mayo Clinic. Casadevall and colleagues observed that while plasma use was declining late last year, the reported COVID-19 patient mortality rate was rising. That led them to hypothesize that the two phenomena were related.

In the study, the researchers compared the number of units of plasma distributed to U.S. hospitals from blood banks, on a per patient basis, to the number of reported COVID-19 deaths per hospital admission across the country.

One finding was that while the total use of plasma peaked last December and January during the winter surge in new COVID-19 patients, the use per hospitalized patient peaked in early October 2020—just as deaths per COVID-19 hospital admission bottomed. Thereafter, in the wake of reports of negative results from clinical trials, use of plasma per hospitalized patient fell sharply—and deaths per COVID-19 hospital admission rose.

The researchers analyzed the relationship between these two datasets and found a strong negative correlation, higher use rate being associated with lower mortality and vice versa. They also grouped periods of plasma use into five “quintile” groupings from lowest-use weeks to highest, and found a graded relationship between less use and higher mortality.

A model the researchers generated to fit the data suggested that the COVID-19 case fatality rate decreased by 1.8 percentage points for every 10-percentage point increase in the rate of plasma use. That model implied that there would have been 29,018 fewer deaths, from November 2020 to February 2021, if the peak use rate of early October had held. Moreover, it suggested that the use of plasma on the whole, as limited as it was, prevented about 95,000 deaths through early March of this year.

The researchers analyzed, and then rejected, the possibility that several other factors could explain away the link between less plasma use and more mortality. These factors included changes in the average age of hospitalized patients, and the emergence of new variants of the COVID-19-causing coronavirus.

As for why some clinical trials found no benefit for plasma use, the researchers note in their paper that many of the clinical trials with negative results had used plasma—mainly considered an antiviral treatment—relatively late in the course of COVID-19, when patients may have been too ill to benefit, and when the disease is driven mainly by immune-related responses rather than the coronavirus itself.

Casadevall notes that convalescent plasma remains under FDA Emergent Use Authorization in the U.S., and that it is readily available. “We hope that physicians, policymakers, and regulators will consider the totality of the available evidence, including our findings, when making decisions about convalescent plasma use in individual COVID-19 patients,” Casadevall says.“Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality” was co-authored by Arturo Casadevall, Quigly Dragotakes, Patrick Johnson, Jonathon Senefeld, Stephen Klassen, R. Scott Wright, Michael Joyner, Nigel Paneth, and Rickey Carter.

There was no specific funding for this study. Individual authors have been supported by the National Institutes of Health (RO1 HL059842; R01 AI152078 9; 5R35HL139854).This project has been funded in whole or in part by the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096.

# # #

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 6123
Released: 4-Aug-2021 5:05 PM EDT
Canadian-Led International Study: Full-Dose Blood Thinners Benefit Moderately Ill COVID-19 Patients
University of Manitoba

The investigators discovered that in moderately ill patients full-dose heparin reduced the need for organ support compared to those who received lower-dose heparin.

Released: 4-Aug-2021 4:00 PM EDT
CDC withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test does not mean the test failed
Newswise

Social media is now rife with claims about why the CDC is withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test after December 2021.

Newswise: Public
Released: 4-Aug-2021 2:05 PM EDT
A Study Reveals What Triggers Lung Damage During COVID-19
The Korea Advanced Institute of Science and Technology (KAIST)

A KAIST immunology research team found that a specific subtype of macrophages that originated from blood monocytes plays a key role in the hyper-inflammatory response in SARS-CoV-2 infected lungs, by performing single-cell RNA sequencing of bronchoalveolar lavage fluid cells.

Released: 4-Aug-2021 1:00 PM EDT
American Society of Anesthesiologists and Anesthesia Patient Safety Foundation Say Preoperative Testing for COVID-19 is Essential, Regardless of Vaccination
American Society of Anesthesiologists (ASA)

All patients undergoing non-emergency surgeries or procedures should continue to have preoperative polymerase chain reaction (PCR) testing for SARS-CoV-2, irrespective of vaccination status, according to an updated guidance from the American Society of Anesthesiologists and Anesthesia Patient Safety Foundation.

Newswise: FAU Expert Answers Questions about Delta Variant, Vaccines and Public Safety
Released: 4-Aug-2021 12:35 PM EDT
FAU Expert Answers Questions about Delta Variant, Vaccines and Public Safety
Florida Atlantic University

Florida Atlantic University’s Joanna Drowos, D.O., M.P.H., M.B.A., Schmidt College of Medicine, provides answers to some of the most frequently asked questions regarding the COVID-19 Delta variant, vaccines and public safety measures.

Released: 4-Aug-2021 11:15 AM EDT
Rehabilitation Nurses Play Critical Role in Treating Patients with Long-Term Covid-19 Symptoms
Association of Rehabilitation Nurses

A new and free webinar from the Association of Rehabilitation Nurses (ARN) and the American Nurses Association (ANA) features advice from rehabilitation nurses to the greater nursing community about care priorities and interventions for long haul COVID-19 patients.

Newswise:Video Embedded spreading-doses-of-hope-as-covid-19-cases-rise
VIDEO
Released: 4-Aug-2021 10:35 AM EDT
Spreading ‘Doses of Hope’ as COVID-19 Cases Rise
Cedars-Sinai

In an emotional new series of videos, Black medical professionals plead for viewers to get a COVID-19 vaccine.

Newswise:Video Embedded american-college-of-surgeons-urges-surgeons-to-talk-it-up-with-patients-about-covid-19-vaccination
VIDEO
Released: 4-Aug-2021 10:00 AM EDT
American College of Surgeons Urges Surgeons to “Talk It Up” with Patients About COVID-19 Vaccination
American College of Surgeons (ACS)

ACS is launching a “Talk It Up” campaign to help surgeons address patient concerns and help them understand the importance of getting vaccinated against COVID-19.

28-Jul-2021 11:15 AM EDT
LEDs Light the Way to Coronavirus Disinfection
American Institute of Physics (AIP)

LEDs are commonly used for sterilization, and in the continued effort to combat the coronavirus pandemic, LEDs can also help inactivate SARS-CoV-2. A team in Pakistan designed far-ultraviolet LEDs at a targeted wavelength of 222 nanometers, chosen both for its ability to inactivate the virus and for being safe on human skin. They based their design on the material aluminum gallium nitride, part of a set of materials called III-nitrides which are efficient, inexpensive, and environmentally friendly.


Showing results

110 of 6123

close
0.98185